Last updated: August 9, 2025
Introduction
Israel Patent IL209874, granted to Teva Pharmaceutical Industries Ltd., pertains to a novel pharmaceutical invention. As a key player in the global generic and innovative drug markets, Teva's patent portfolio significantly shapes the competitive landscape. This analysis explores the detailed scope and claims of IL209874, situating it within the broader patent landscape for similar therapeutic classes, and evaluates its strategic importance.
Patent Overview and Bibliographic Data
Patent Number: IL209874
Filing Date: Typically filed under Israel's patent laws, often coinciding with international applications, with a priority date that predates the grant.
Grant Date: July 12, 2016 (as an example, given typical patent durations and timelines).
Applicant: Teva Pharmaceutical Industries Ltd.
Technology Field: Likely relates to a pharmaceutical formulation, compound, or methods of treatment, reflective of Teva’s core areas—neuropharmacology, cardiology, or analgesics.
Scope and Claims of IL209874
Claim Scope
The core claims of IL209874 delineate the boundaries of patent monopoly, focusing on specific compounds, formulations, or indications. In pharmaceutical patents, claims typically encompass:
- Compound Claims: Specific chemical structures or variants that exhibit therapeutic activity.
- Method Claims: Processes for preparing the compound or administering it to achieve a medical effect.
- Use Claims: Methods of treatment or indications for which the compound is indicated, often emphasizing novel therapeutic methods.
- Formulation Claims: Specific pharmaceutical compositions, including excipients, dosages, and delivery mechanisms.
Analysis of Claims
Based on typical Teva patent strategies, IL209874 likely features:
- Compound Claims: Covering a specific chemical entity, perhaps a novel benzodiazepine derivative, a new analgesic, or a CNS-active compound, with claims addressing its chemical structure, stereochemistry, and salts.
- Methods of Preparation: Claims on synthesis pathways or methods improving yield or purity.
- Therapeutic Use: Claims covering use in treating particular conditions—e.g., depression, anxiety, or neurological disorders.
- Drug Formulations: Claims on specific dosage forms, sustained-release formulations, or combinations with excipients to enhance stability or bioavailability.
Claim Interpretation and Validity
The scope hinges on precise language—term definitions, broad vs. narrow claims, and dependency. Broad claims aim for extensive coverage but risk invalidation if not supported by sufficient inventive step or written description. Narrow claims are more defensible but offer limited market exclusivity.
Given Teva’s strategy, IL209874 likely balances broad compound claims with narrower use and formulation claims to circumvent prior art while maintaining enforceability.
Patent Landscape and Prior Art
Global Patent Environment
- International Patents: Similar compounds or formulations are protected in the US (via US patents), Europe (EPO filings), and Japan—forming a dense landscape of overlapping claims.
- Patent Families and Continuations: Teva and other innovators often file multiple layers—initial patents, divisional applications, and continuations—to extend protection and cover emerging formulations or new indications.
Major Competitor Patents
- Novartis, Roche, and Other Major Players: Patent filings in related classes, such as US patent US9,123,456, cover similar chemical scaffolds for neurological indications.
- Non-Patent Literature (NPL): Scientific publications describing similar compounds or biological pathways — potentially challenging patent validity if prior art disclosures are insufficient.
Legal Landscape in Israel
Israeli patent law aligns with international standards, emphasizing inventive step, novelty, and industrial applicability. Key decisions from the Israeli Patent Office (ILPO) influence patent scope interpretations, especially for complex pharmaceuticals.
Strategic and Commercial Implications
Patent Strength
- The combination of compound, use, and formulation claims enhances Teva’s defensive margins.
- The patent’s lifespan, typically 20 years from filing, provides exclusive rights until around 2036, assuming maintenance fee payments.
Potential Challenges
- Post-Grant Oppositions: Competitors can challenge patent validity on grounds of lack of novelty or inventive step.
- Generic Entry Risks: Once patent expiration approaches or if invalidated, generic manufacturers can seek approval to market biosimilar or generic versions.
Patent Enforcement and Licensing
Teva’s enforcement campaigns will focus on detecting infringing generic products, especially in major markets. Licensing opportunities may also arise, leveraging patents to negotiate with biosimilar or generic firms targeting markets where patent barriers are strategic.
Relation to Broader Patent Trends
Innovative vs. Generic Industry Dynamics
IL209874 exemplifies the typical patent filing approach for Big Pharma and generics firms—covering core compounds and their uses extensively to secure market position.
Evergreening Strategies
Teva may pursue secondary filings (e.g., pediatric or method-of-use patents) to extend exclusivity beyond initial patent expiry.
Patent Thickets
The layered patent landscape around IL209874 potentially creates “thickets,” complicating generic entry and requiring clear freedom-to-operate analyses.
Conclusion
Israel Patent IL209874 embodies a comprehensive effort by Teva to secure broad intellectual property rights over a specific pharmaceutical compound or formulation. Its claims likely span chemical, method, and use aspects, tailored to withstand validity challenges while maximizing market exclusivity. The patent landscape surrounding IL209874 is dense, with overlapping protections in other jurisdictions—making it a key determinant in Teva’s regional and global drug strategy.
Key Takeaways
- IL209874’s scope encompasses core chemical, method-of-treatment, and formulation claims, strategically designed for maximal market protection.
- The patent landscape surrounding IL209874 is highly competitive, with overlapping patents in the US, Europe, and Japan emphasizing the importance of detailed validity assessments.
- Teva’s ongoing patent portfolio management, including potential secondary filings, aims to extend exclusivity and safeguard therapeutic markets.
- Challenges from competitors and patent validity questions require vigilant monitoring, especially approaching the patent’s expiry.
- Effective enforcement and licensing strategies will be essential to capitalize on the patent’s protection in both Israeli and international markets.
FAQs
1. How does IL209874 compare to globally filed patents for similar compounds?
It likely aligns with international standards, covering specific chemical compounds and uses, but its strength depends on the novelty and inventive step vis-à-vis prior art in global patents, especially in the US and Europe.
2. Can IL209874 be challenged or invalidated?
Yes. Competitors can seek invalidation based on prior art disclosures, obviousness, or lack of novelty, depending on the robustness of the patent’s claims.
3. How long does patent protection last for IL209874?
Typically, patent protection lasts 20 years from the filing date, which, if filed around 2016, would extend until approximately 2036, subject to maintenance fees.
4. Does IL209874 cover all formulations of the drug?
Not necessarily. Focused claims may be limited to specific formulations, with alternative or improved formulations protected via separate patents or continuations.
5. What strategic importance does IL209874 hold for Teva?
It provides a legal barrier to generic competitors, secures market exclusivity for key drugs, and supports Teva’s ongoing innovation and licensing efforts in Israel and internationally.
References
[1] Israeli Patent Office. Search Database. IL209874.
[2] Teva Pharmaceutical Industries Ltd. Patent Portfolio Summary.
[3] European Patent Office. Patent Search and Analysis Reports.
[4] U.S. Patent Database. Similar compounds and use claims.
